Hoth Therapeutics (NASDAQ: HOTH) Could Be the Next 100% RunnerHoth Therapeutics, Inc. (NASDAQ: HOTH) shares are down slightly by 1.83% in Thursday’s trading session, but the technical outlook suggests a major breakout could be on the horizon. A fully formed falling wedge pattern has developed on the chart, and liquidity has been swept to the downside. The stock attempted to break out of this wedge in early March 2025, but the move was faded due to broader market consolidation, influenced by recent uncertainties surrounding Trump’s tax policy. However, the current setup indicates that a breakout remains imminent, with a potential 100% surge in sight.
The 12-hour chart shows that the Relative Strength Index (RSI) currently sits at 50.66, positioning the stock in a neutral zone. This is a strong indicator that NASDAQ: HOTH could gain traction as buyers begin to accumulate, capitalizing on its stability. The stock’s ability to maintain strength at this level suggests that momentum could shift rapidly if bullish pressure increases.
Key Fibonacci retracement levels are also aligning with this bullish setup. The 65% and 61.8% Fibonacci zones are acting as the primary breakout points, which correspond to the $1.40–$1.50 price range. If NASDAQ: HOTH successfully breaks through these levels, a strong upward move could follow, validating the 100% surge potential. This setup is further reinforced by increasing trading volume and early signs of buyer interest, which could trigger the anticipated breakout.
With volume ticking up and key resistance levels within reach, Hoth Therapeutics, Inc. (NASDAQ: HOTH) shares are shaping up for a move that could catch many off guard. Historically, setups like this don’t stay quiet for long—once momentum kicks in, those on the sidelines may find themselves chasing the action.
About Hoth Therapeutics, Inc. (NASDAQ: HOTH)
Founded in 2017, Hoth Therapeutics, Inc. (NASDAQ: HOTH). is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for unmet medical needs. Headquartered in New York, the company focuses on advancing treatments across multiple therapeutic areas, including dermatology, oncology, neurology, and immunology.
Important Dates
The next estimated earnings date is Thursday, March 27, 2025, after market close.
Analysts Ratings
Hoth Therapeutics (NASDAQ: HOTH) has garnered strong support from analysts, with a 12-month average price target of $4.75, representing a potential upside of 339.81% from the current price of $1.08. Analysts have given HOTH a "Strong Buy" rating, signaling confidence in the stock's growth potential.
With institutional interest rising and Hoth targeting multi-billion-dollar healthcare markets, this stock offers an opportunity for both immediate momentum and long-term growth.
Don’t overlook Hoth Therapeutics (NASDAQ: HOTH)—a major breakout could be on the horizon.
